Navigation Links
FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications
Date:4/8/2009

ent.com/prnews?Page=Quote&Ticker=AZN'> AZN) is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business. For more information about AstraZeneca in the US or our AZ&Me? Prescription Savings programs, please visit: www.astrazeneca-us.com.

The statements contain herein include forward-looking statements. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of the preparation of this press release and the Company undertakes no obligation to update these forward-looking statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those risk factors identified in the Company's Annual Report/Form 20-F for 2007. Nothing contained herein should be construed as a profit forecast.

NOTES TO EDITORS:

    Questions to the Advisory Committee              Yes   No   Abstain
    1. Has SEROQUEL XR been shown to be effective
     as a treatment of:
    -- MDD as an adjunct therapy?                      9    1        0
    -- MDD as a monotherapy?                           8    1        1
    -
'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
4. Patient Safety Authority Board of Directors Names Infection Advisory Panel
5. Broker a Suite of Research & Advisory Services to Enhance Human Resources
6. Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council
7. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Alter+Care Creates the Advisory Board
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Good Neighbor Community Services ... upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , In this segment, ... Services’ vision to redefine the traditional approach to ... services. Through passion, innovation, determination, excellence, and collaboration, ...
(Date:7/30/2014)... By Alan Mozes ... -- Parents who want to help their preschooler shed excess ... research suggests. Youngsters whose parents joined them in a ... who were enrolled in a traditional child-only program (an average ... partners also benefited, losing almost 15 pounds over two years, ...
(Date:7/30/2014)... 30, 2014 Volunteers from the Church ... drug abuse this summer with massive distribution of ... can find these volunteers on Strøget, the famous Copenhagen ... for its shopping and its ambiance, some quarter of ... typical summer day. , These activities are part ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 ... authentication, access management and secure communications solutions for ... OneSign ® is the most widely selected single ... Paragon or Horizon electronic medical records (EMR) systems ... of about 11 percent in the last 12 ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... Researchers at the University of Texas, have shown that use ... cancer.Up to 70 per cent of US women born since ... suggested that use of the hormones in the Pill could ... have failed to reveal a connection. The early Pill users ...
... to day problem among the adolescents. Every day, more than ... young smokers will eventually die from tobacco-related causes.// A new ... are among the driving forces causing young girls to become ... Institute, followed more than 1,500 young girls, beginning at ages ...
... of taking care your medication. Sometimes half a pill does the ... a medication, or be given a double dose of a medicine ... into two or more doses. ,Doctors at the Mayo ... splitting. First, you need to check if your pill is amenable ...
... darkness might prevent retinal damage in diabetes. One of the ... diabetic retinopathy. This results from damage to the retina //- ... which responds to light.In diabetes, the blood supply to the ... rods (the cells responsible for night vision) which have a ...
... a type of ultrasound test may be able to identify ... most common causes of sudden death in young people.The condition, ... different mutations in as many as 10 genes. In HCM, ... pump blood and putting patients at risk of heart failure ...
... at home reduces hospitalisation in those with lung disease. Researchers ... of oxygen on 200 patients with smoker's lungs - where ... in an outpatient clinic, then continued at home. ... proved to be beneficial. The patients had a 40 per ...
Cached Medicine News:Health News:What makes young girls smoke 2Health News:Ultrasound test may detect heart condition early 2
(Date:7/30/2014)... Company expands reach of ... big data, aerospace and defense, medical, and industrial, ... engineering R&D services company, today announced professional services ... for aerospace and defense , medical ... industrial , and visual computing applications. ...
(Date:7/29/2014)... Israel , July 30, 2014  Immune ... Stockholm : "IMNP."; "Immune" or "the ... of patients for a Phase II proof of concept ... in the treatment of moderate to severe bullous pemphigoid. ... receive two bertilimumab infusions, at a dose of 10 ...
(Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
Breaking Medicine Technology:eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: